Dr. Stanley Hazen received both clinical training in Internal Medicine and subspecialty training in Diabetes, Endocrinology and Metabolism from Barnes/Jewish Hospital, St. Louis, MO, and a PhD in Biophysical Chemistry and Molecular Biology from Washington University School of Medicine, St. Louis, MO.
He holds multiple leadership positions at the Cleveland Clinic including chair of the Department of Cardiovascular &amp; Metabolic Sciences, Lerner Research Institute, co-Section head of Preventive Cardiology &amp; Rehabilitation, Heart, Vascular &amp; Thoracic Institute, and Director, Center for Microbiome &amp; Human Health, Cleveland Clinic.
Dr. Hazen (H-index 149; citations &gt;148,000) ranks among the top 0.1% cited scientists and physicians worldwide in all fields of science and medicine. He has published &gt;475 peer-reviewed articles in basic and clinical journals alike in the fields of atherosclerosis, metabolism, inflammation and vascular biology. He has made pioneering discoveries in new understandings of mechanisms contributing to cardiovascular and inflammatory disease research, including the seminal discovery linking gut microbial pathways to cardiovascular disease pathogenesis. His research in multiple areas has impacted clinical practice and lays the foundation for both FDA- and EU-cleared diagnostic tests for CVD risk assessment in use worldwide. His research has also helped to spawn pharmaceutical development of cardiovascular disease drugs in clinical trials.
Dr. Hazen is an elected fellow to the National Academy of Medicine, USA. He also is an elected fellow of the American Association for the Advancement of Science., and is an elected member of the prestigious honorary society the American Association of Physicians.

Stanley Hazen, MD, PhD